The following patients were excluded: those who were not diagnosed with NSCLC or pancreatic cancer (n = 8), had underlying liver diseases (n = 14), had an elevated AST or ALT value on day one of erlotinib administration (n = 30), and those without liver function test results (n = 36). This evidence concerns the gene GPT and liver disorder.